<?xml version="1.0" encoding="UTF-8"?>
<p id="Par67">Only 0.0004% plant samples may directly lead to a commercial drug (Chinsembu 
 <xref ref-type="bibr" rid="CR16">2016a</xref>). Thus, there are few plant-derived anti-SARS agents in clinical trials. From 2012 to 2017, only twelve new antivirals were approved by the US Food and Drug Administration; eight were for the treatment of pathologies related to hepatitis C virus and two were combinations of anti-HIV drugs (Mercorelli et al. 
 <xref ref-type="bibr" rid="CR80">2018</xref>). Since less than 15% of plant diversity has been explored for pharmaceutical purposes (Chinsembu, 
 <xref ref-type="bibr" rid="CR16">2016a</xref>), the transition from natural product to anti-SARS-CoV-2 drug prototypes is a daunting reality as much as it is a beautiful prospect.
</p>
